12 Best Weight Loss Stocks to Buy According to Hedge Funds

5. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 62 

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is involved in the discovery, development, manufacturing, and marketing of medicines for serious medical conditions such as cancer, eye diseases, allergies, inflammation, and rare diseases. Its key products include Eylea for retinal diseases, Dupixent for immunological disorders, and Libtayo for cancer treatment. The company has over 35 candidates in its development pipeline.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is developing two monoclonal antibodies, Trevogrumab, and Garetosmab, to preserve lean muscle mass during weight loss, in combination with incretin-based treatments like Semaglutide (Wegovy) and Trzepatide. Trevogrumab inhibits myostatin, promoting muscle growth, while Garetosmab targets activin A to prevent muscle deterioration. These antibodies aim to reduce muscle loss, which can make up to 40% of total weight loss, thus improving long-term health outcomes. The corporation is also addressing post-treatment weight maintenance by combining these antibodies with existing weight loss drugs to promote sustainable weight loss and healthier body composition which places Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) among the best weight loss stocks.

Additionally, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is collaborating with AstraZeneca to develop small molecule drugs targeting the GPR75 gene, associated with lower obesity risk, aiming for patient-friendly oral treatments. Their Genetics Center has uncovered genetic mutations, such as in GPR75, that protect against obesity, leading to new therapeutic avenues for obesity treatments, including antibody, small molecule, and gene silencing approaches.

In Q3 2024, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong financial results with total revenue growing by 11% to $3.72 billion, exceeding expectations. Key drivers included Dupixent, which saw a 23% rise in sales to $3.82 billion, and Libtayo, which grew by 24%. R&D expenses increased by 18%, signaling the company’s focus on expanding its pipeline, including obesity treatments. The company’s net income rose by 33%, with GAAP EPS increasing by 30% which reflects strong operational performance.